PORTLAND, ME–(EMWNews – August 4, 2008) – ImmuCell Corporation (NASDAQ: ICCC) today

announced the results of its operations for the three and six month periods

ended June 30, 2008.

For the three-month period ended June 30, 2008, product sales increased by

4%, or $35,000, to $826,000 in comparison to the same period in 2007. For

the six-month period ended June 30, 2008, product sales increased by 7%, or

$157,000, to $2,457,000 in comparison to the same period in 2007.

“In this very challenging economic environment, we are gratified that our

customers have rewarded us with an 8% increase in sales our lead product,

First Defense®, during the six-month period ended June 30, 2008,”

commented Michael F. Brigham, President and CEO. “First Defense® sales

continue to be seasonal with lower sales expected during the second and

third quarters.”

Product development expenses increased by 44%, or $130,000, to $423,000

during the three-month period ended June 30, 2008 in comparison to the same

period in 2007. Product development expenses increased by 35%, or

$195,000, to $755,000 during the six-month period ended June 30, 2008 in

comparison to the same period in 2007.

The net loss was $(238,000) (or $(0.08) per share) during the three-month

period ended June 30, 2008 in comparison to a net loss of $(60,000) (or

$(0.02) per share) during the same period in 2007. Technology licensing

revenue decreased by $158,000 (100%) and product development expenses

increased by $130,000 during the comparable periods.

The net loss was $(160,000) (or $(0.06) per share) during the six-month

period ended June 30, 2008 in contrast to net income of $237,000 (or $0.08

per diluted share) during the same period in 2007. Technology licensing

revenue decreased by $316,000 (100%) and product development expenses

increased by $195,000 during the comparable periods.

“Our net loss reflects our strategic decision to make a significant and

controlled investment in the development of Mast Out®, which entered into

its pivotal effectiveness trial during the second quarter,” commented Dr.

Joseph H. Crabb, Vice President and Chief Scientific Officer.

Cash, cash equivalents and short-term investments increased by 5%, or

$283,000, to $5,695,000 at June 30, 2008 as compared to $5,412,000 at

December 31, 2007. Stockholders’ equity decreased by 1%, or $106,000, to

$9,951,000 at June 30, 2008 as compared to $10,057,000 at December 31,

2007. The Company had 2,895,000 shares of common stock outstanding as of

June 30, 2008.

                                         (Unaudited)       (Unaudited)

                                       Three Months Ended Six Months Ended

                                           June 30,          June 30,

                                        ----------------  ----------------

(In thousands, except per share

 amounts)                                 2008     2007     2008     2007

                                        -------  -------  -------  --------

Revenues:

Product Sales                           $   826  $   791  $ 2,457  $  2,300

Other Revenues                               --      168        5       335

                                        -------  -------  -------  --------

Total Revenues                              826      959    2,462     2,635



Cost and expenses:

Product costs                               447      511    1,261     1,141

Product development expenses                423      294      755       560

Selling, general and administrative

 expenses                                   351      307      772       656

                                        -------  -------  -------  --------

Total costs and expenses                  1,221    1,112    2,788     2,357

                                        -------  -------  -------  --------



Net operating (loss) income                (395)    (153)    (326)      278



Interest and other income                    56       70      116       146

                                        -------  -------  -------  --------



(Loss) income before income taxes          (339)     (83)    (210)      424

Income tax (benefit) expense               (101)     (23)     (50)      187

                                        -------  -------  -------  --------

Net (loss) income                       $  (238) $   (60) $  (160) $    237

                                        =======  =======  =======  ========



Net (loss) income per common share:

Basic                                   $ (0.08) $ (0.02) $ (0.06) $   0.08

Diluted                                 $ (0.08) $ (0.02) $ (0.06) $   0.08

                                        =======  =======  =======  ========



Weighted average common shares

 outstanding:

Basic                                     2,893    2,903    2,893     2,900

Diluted                                   2,893    2,903    2,893     3,066





                                          (Unaudited)

                                          At June 30,    At December 31,

(In thousands)                               2008             2007

                                        ---------------  ---------------

Cash, cash equivalents and short-term

 investments                            $         5,695  $         5,412

Total assets                                     10,302           10,412

Net working capital                               6,746            6,710

Stockholders' equity                    $         9,951  $        10,057

ImmuCell Corporation is a biotechnology company that is developing,

manufacturing and selling products that improve animal health and

productivity in the dairy and beef industries. Press releases and other

information about the Company are available at http://www.immucell.com.

Contact: Michael F. Brigham President and Chief Executive Officer (207) 878-2770 Ext. 3106